Societal Costs

Societal Costs

Societal cost savings through bevacizumab-based treatment in non-small cell lung cancer (NSCLC)
Stanisic S, Bischoff HG, Heigener DF, Vergnenègre A,de Castro Carpeño J, Chouaid C, Walzer S, Mueller E, Schmidt E; Lung Cancer 2010: 69S1 (2010): S24-S30